WO2009113594A1

WO2009113594A1 - Agent and food for prevention/amelioration of functional gastrointestinal disorders

Info

Publication number: WO2009113594A1
Application number: PCT/JP2009/054697
Authority: WO
Inventors: 真一藤田; 郁美石橋; 沙織小川; 学鈴木
Original assignee: 味の素株式会社
Priority date: 2008-03-11
Filing date: 2009-03-11
Publication date: 2009-09-17
Also published as: EP2263666A4; EP2263666A1; JPWO2009113594A1; US20110060046A1

Abstract

Disclosed is a prophylactic/ameliorating agent for functional gastrointestinal disorders, which comprises glutamic acid or a salt thereof and arginine or a salt thereof (excluding glutamic acid arginine salt) as active ingredients. The prophylactic/ameliorating agent can be produced conveniently at a low cost, is highly safe, and is effective particularly for upper gastrointestinal functional disorders such as functional dyspepsia (FD) including abdominal pain, heavy stomach feeling and burning pain and gastroesophageal reflux disease (GERD).

Description

Functional gastrointestinal disorder preventive / ameliorating agent and food

The present invention relates to a functional gastrointestinal disorder preventive / ameliorating agent, and more particularly, functional gastroenteropathy such as abdominal pain, stomach sag, heartburn, etc., among functional gastrointestinal disorders (FGIDs). The present invention relates to a preventive / ameliorating agent for upper gastrointestinal dysfunction of (FD) and gastroesophageal reflux disease (GERD).

Even if endoscopic diagnosis advances, there are many cases in which symptoms cannot be explained for complaints of upper gastrointestinal symptoms such as upper abdominal pain and discomfort, stomach upset after meals, nausea and vomiting. In general examinations that include endoscopes while complaining of such gastrointestinal symptoms, there are no organic diseases, and no findings to clarify the symptoms can be found. Functional gastrointestinal disorders, especially functional gastroenteropathy (FD: This is called functional dyspepsia, non-ulcer dyspepsia (NUD).
The Rome standard is known as a diagnostic standard for functional gastrointestinal disorders, but was revised in April 2006 and published in the American Society of Gastroenterology as Rome III. Although there is no major change in the concept of FD, dyspepsia symptoms in the diagnostic criteria have been simplified to four based on the results of clinical studies after Rome II. That is, annoying after-prandial fullness, early satiation, epigastric pain, epigastric burning, and one or more symptoms are chronic (strict) Is diagnosed as FD when organic disease is excluded. On the other hand, in Japan, these cases have been referred to as “upper abdominal gastrointestinal complaints associated with chronic gastritis” regardless of their organic findings, and have been conventionally diagnosed as “gastritis” or “chronic gastritis” in clinical practice. Exists.

On the other hand, even when organic lesions (reflux esophagitis, peptic ulcer, acute gastritis, gastrointestinal cancer, pancreatic / biliary tract disease, etc.) are clearly associated, abdominal pain and discomfort, stomach upset after meals, nausea / Vomiting and the like have been observed, and these improvements in discomfort are urgently needed to improve the patient's QOL. When combined with NUD and lower abdominal gastrointestinal complaints such as difficulty of defecation associated with constipation, abdominal pain, abdominal bloating, etc., approximately 30% to 50% of the total population in Japan has some unidentified complaints of the digestive tract It is speculated that you have experienced. Abdominal indefinite complaints are thought to be affected by gender, aging, stress, and obesity due to Western dietary habits. Abdominal indefinite complaints can be said to be a disease that represents modern society along with lifestyle-related diseases. . Although it is such a serious disease, the cause of gastrointestinal indefinite complaints has only been suggested to be associated with various diseases (chronic gastritis, diabetes, obesity, constipation, etc.). Only a decrease in gastrointestinal motor function has been suggested. Considering that 50% of the actual FD patients have decreased gastrointestinal motility, it is clear that the mechanism of FD development has not been fully elucidated.

Many patients with progressive cerebral degenerative diseases such as Parkinson's disease, Huntington's disease, olive bridge cerebellar atrophy, and stroke patients also have dysfunction of the gastrointestinal tract. It is said that it is necessary. Among these patients, it is thought that there are many patients who are unable to complain of indefinite complaints for reasons such as speech disorder or consciousness disorder, and remove sensory disturbances such as indefinite complaints at the same time as care for organic dysfunction. Caring for care leads to a real QOL improvement.

So far, 5-HT4 receptor agonists and the like have been used for the treatment of FD. For example, cisapride and metoclopramide have a gastrointestinal motility enhancing action and are used for the treatment of symptoms such as chronic gastritis, abdominal fullness, reflux esophagitis, abdominal indefinite complaints, and pseudointestinal obstruction. However, metoclopramide has been shown to have side effects of extrapyramidal symptoms on its action on central dopamine D ₂ receptors, and it has been shown that Parkinson's symptoms also appear in cisapride. Furthermore, although mosapride and the like are used, the effect may not be sufficient, and side effects such as diarrhea appear. Moreover, there are many cases where H2 antagonists and proton pump inhibitors are prescribed, but their safety is uncertain when administered over a long period of time. There is also a report that long-term administration of a proton pump inhibitor increases the risk of fractures.

On the other hand, glutamic acid has been reported to be a preventive / ameliorating agent for functional gastrointestinal disorders. Furthermore, arginine glutamate has also been reported to be a preventive / ameliorating agent for gastrointestinal disorders (Patent Document 1). On the other hand, arginine has been suggested to increase the frequency of occurrence of myocardial infarction, but the preventive / ameliorating agent in which the mixing ratio of glutamic acid and arginine is changed is not known.
WO2006 / 030980 A1

The present invention can be more easily produced in order to prevent or ameliorate functional gastrointestinal disorders, particularly upper gastrointestinal dysfunction such as functional gastroenteropathy and gastroesophageal reflux disease such as abdominal pain, stomach upset and heartburn. The object is to provide a highly safe preventive / ameliorating agent.

The present invention has been made in view of the above problems. The present inventors have found that administration of a preparation containing glutamic acid and arginine promotes gastric emptying, which is effective for functional gastrointestinal tract disorders in which gastric emptying is delayed. Moreover, it became clear that the same effect was shown even if the ratio of arginine was changed, and it discovered that the quantity of arginine which is a bitter substance and needs masking at the time of ingestion can be reduced.

That is, the present invention is as follows.
[1] A functional gastrointestinal disorder preventive / ameliorating agent containing glutamic acid or a salt thereof, and arginine or a salt thereof as an active ingredient, except for glutamic acid arginine salt.
[2] The preventive / ameliorating agent according to [1], wherein the functional gastrointestinal tract disorder is upper gastrointestinal tract disorder.
[3] The preventive / ameliorating agent according to [2], wherein the upper gastrointestinal dysfunction is functional gastroenteropathy or gastroesophageal reflux disease.
[4] The preventive / ameliorating agent according to any one of [1] to [3], wherein the molar ratio of glutamic acid or a salt thereof to arginine or a salt thereof is blended at 30: 1 to 1:30.
[5] The preventive / ameliorating agent according to [4], wherein the molar ratio is 10: 1 to 1:10.
[6] The preventive / ameliorating agent according to [4], wherein the molar ratio is 10: 1 to 2: 1 and 1: 2 to 1:10.
[7] The preventive / ameliorating agent according to [4], wherein the molar ratio is 10: 1 to 2: 1.
[8] A medicament comprising the preventive / ameliorating agent according to any one of [1] to [7].
[9] A food containing the preventive / ameliorating agent according to any one of [1] to [7].
[10] The food according to [9], wherein the food is a health functional food, a food for specified health use, a nutritional functional food, or a dietary supplement.
[11] A method for preventing or ameliorating functional gastrointestinal disorders, comprising administering an effective amount of glutamic acid or a salt thereof, and arginine or a salt thereof to a subject suffering from a functional gastrointestinal disorder, wherein glutamic acid arginine salt is except.
[12] A method for treating functional gastrointestinal disorders, comprising administering an effective amount of glutamic acid or a salt thereof, and arginine or a salt thereof to a subject suffering from functional gastrointestinal disorders, except for glutamic acid arginine salts .
[13] Use of glutamic acid or a salt thereof and arginine or a salt thereof for producing the preventive / ameliorating agent according to [1] to [7], except for glutamic acid arginine salt.
[14] The preventive / ameliorating agent according to any one of [1] to [7], which is a solid preparation.

ADVANTAGE OF THE INVENTION According to this invention, the chemical | medical agent and foodstuffs which are useful for improvement of functional digestive tract disorders, especially upper gastrointestinal dysfunctions, such as functional gastroenteropathy and gastroesophageal reflux disease, can be provided. Further, the drug or food can be taken for a long time because it improves the unpleasant sensation associated with the above-mentioned diseases, increases the QOL of the patient, and has few side effects. Further, when the amount of arginine, which is a bitter substance and requires masking when ingested, is small, masking is easily performed. On the other hand, when the amount of arginine is large, effects such as difficulty in causing postprandial satiety in patients with functional gastrointestinal disorders, particularly functional gastroenteropathy, can be obtained. It also has the effect of suppressing symptoms associated with reflux even in patients with gastroesophageal reflux disease.
Furthermore, according to the present invention, it is possible to easily produce drugs and foods by adding only glutamic acid (its salt) and arginine (its salt) without forming a salt or the like.

FIG. 1 shows the results of promotion of gastric emptying when the mixing ratio of glutamic acid and arginine is changed. FIG. 2 shows the results of promotion of gastric emptying when the mixing ratio of glutamic acid and arginine is changed.

Hereinafter, embodiments of the present invention will be described.
A functional gastrointestinal tract preventive / ameliorating agent (hereinafter also referred to as the prophylactic / improving agent of the present invention) containing glutamic acid or a salt thereof of the present invention and arginine or a salt thereof as an active ingredient (excluding glutamic acid arginine salt) is a patient To prevent or improve the occurrence of the following symptoms in reproducible functional gastrointestinal disorders, particularly functional gastroenteropathy, gastroesophageal reflux disease and the like.

“Functional gastrointestinal tract disorder” in the present invention refers to a state in which the motor function of the digestive tract is reduced despite no obvious organic change, and the digestive tract (pharynx, esophagus, stomach, small intestine). (Deduodenum, jejunum, ileum), large intestine) is a decrease in all functions. In Rome III, this definition is classified from A to H. Functional esophageal disorder, functional gastroduodenal disorder, functional bowel disorder, functional abdominal pain syndrome, functional gallbladder / oddy sphincter disorder, functional Anorectal disorders, neonatal and infant dysfunction, children and adolescent dysfunction.

The “gastrointestinal tract” in the present invention refers to a luminal organ involved in a series of digestion from the oral cavity to the anus, and includes, for example, the pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), and large intestine. Furthermore, the “upper digestive tract” refers to the pharynx, esophagus, stomach, and duodenum.

`` Functional gastroenteropathy '' in the present invention refers to a disease that has been diagnosed as chronic gastritis or gastritis with delayed gastric emptying, and is characterized by symptoms such as abdominal pain, stomach upset, heartburn, etc. To do. According to RomeIII, one or more symptoms of annoying postprandial fullness, early satiety, epigastric pain, and epigastric burning sensation were chronic (exactly 3 months or more), and organic diseases were excluded. Sometimes diagnosed with functional gastroenteropathy.

“Gastroesophageal reflux disease” in the present invention includes reflux esophagitis, which is a symptom caused by reflux of gastric acid and having specific symptoms such as heartburn and gastric acid rising to the mouth.

Specific symptoms (indefinite complaints) of functional gastrointestinal disorders that can be prevented or ameliorated by the preventive / ameliorating agent of the present invention include nausea, vomiting, nausea, heartburn, bloating, stomach upset, gep, chest distress, Typical upper gastrointestinal complaints such as chest pain, stomach discomfort, loss of appetite, lower gastrointestinal complaints such as abdominal pain, constipation, and diarrhea and related complaints such as shortness of breath, difficulty in breathing, decreased motivation, laryngeal obstruction, foreign body Sensation ("Umekiki" in Chinese medicine), ease of fatigue, stiff shoulders, tension, dry mouth (dry thirst, dry mouth), respiratory distress, extremity heat / cold sensation, difficulty concentrating, agitation, sleep disorder, Examples include headache, general malaise, palpitation, night sweats, anxiety, lightness, dizziness, heat, hot flashes, sweating, abdominal pain, constipation, and depression.

The preventive / ameliorating agent of the present invention is used for the prevention or improvement of functional gastrointestinal disorders. Improvement here is a concept including improvement of symptoms and prevention of progression (deterioration) of medical conditions or symptoms. Prevention is also a concept that includes preventing the occurrence of symptoms (prevention) and reducing the risk of functional gastrointestinal disorders.

Glutamic acid, arginine, and salts thereof may be any of those derived from animals and plants, or those obtained by chemical synthesis, fermentation, or gene recombination. In glutamic acid, any of L-form, D-form and a mixture thereof (for example, racemate) may be used, but L-form is preferably used. In addition, it is speculated that aspartic acid, tricolominic acid, ibotenic acid, or salts thereof, which are the same amino acids as glutamic acid, have an action to improve functional gastrointestinal tract disorders.

Arginine may be any of L-form, D-form, and a mixture thereof (for example, racemate), but L-form is preferably used.

The glutamic acid salt and arginine salt in the present invention include pharmacologically acceptable salts. Examples of such salts include salts with inorganic bases, salts with inorganic acids, salts with organic acids, and the like. However, arginine glutamate is excluded as the above salt.

Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and a salt with ammonium.
Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
Examples of salts with organic acids include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid, glutamic acid, aspartic acid, histidine and the like.
Among these, a salt with an alkali metal such as a sodium salt is preferable, and a salt with an organic acid such as a histidine salt is also useful.

Suitable glutamic acid or a salt thereof as an active ingredient includes glutamic acid, sodium L-glutamate, sodium D-glutamate and the like. Of these, glutamic acid, sodium L-glutamate and the like are preferable.
Arginine or a salt thereof as a suitable active ingredient includes arginine, arginine hydrochloride and the like.
Moreover, an active ingredient can be used in mixture of 2 or more types.

In the preventive / ameliorating agent of the present invention, the ratio of glutamic acid or a salt thereof to arginine or a salt thereof is usually such that glutamic acid and arginine are blended at a molar ratio of 100: 1 to 1: 100 (1: 1 is Preferably excluded). Among these, 30: 1 to 1:30 is preferable, and 10: 1 to 1:10 is more preferable (1: 1 is preferably excluded). In particular, the range of 10: 1 to 2: 1 and 1: 2 to 1:10 is preferable, and 10: 1 to 2: 1 is particularly preferable.

Administration subjects are individuals suffering from functional gastrointestinal disorders (for example, humans, domestic animals and poultry such as cows, horses, pigs, sheep, dogs, and birds, and laboratory animals such as mice and rats. The same applies hereinafter). And individuals who may suffer from the functional gastrointestinal tract disorder.

In the present invention, “active ingredient” refers to an ingredient that provides a desired preventive / improving effect. The dose of the active ingredient varies depending on the sex, age, weight, diet, mode of administration, FD symptom, degree of risk of inducing FD, symptoms of organic diseases of the digestive tract, etc. The daily dose of the active ingredient relative to (with a body weight of 60 kg) is usually 0.01 to 10 g, preferably 0.1 to 3 g as glutamic acid. Similarly, arginine is usually 0.01 to 10 g, preferably 0.1 to 3 g.

The daily dose of the active ingredient in which glutamic acid and arginine are combined is preferably 0.01 to 20 g, more preferably 0.01 to 10 g, still more preferably 0.1 to 6 g as glutamic acid and arginine.
Such a dose can be administered once or divided into several times.

As described above, in the present invention, functional gastrointestinal tract disorders are improved by administering an effective amount of the above-mentioned active ingredient to the administration subject. In this case, the active ingredient is administered as it is or mixed with a pharmaceutical carrier. Taking into account the amount of active ingredient to be administered and the condition of the administration subject (eg patient), tablets (including sugar-coated tablets and film-coated tablets), pills, capsules, ampoules, sachets, elixirs Can be administered orally, enterally or parenterally as pharmaceutical preparations such as pills, suspensions, syrups, gum preparations, drops preparations, powders, granules, injections, suppositories, sustained-release preparations, etc. . As an administration method, oral administration is preferable, and a drug sustained release form is more preferable. Examples of sustained release forms include gum preparations, drops preparations, stereotactic release agents (pyloric rupture preparations) and the like in addition to usual sustained release agents such as gel-coated preparations and multiple-coated preparations.
The preventive / ameliorating agent of the present invention is preferably in the form of a solid preparation such as powder, granule, fine granule, tablet and capsule.
Furthermore, the present invention also includes a form in which glutamic acid or a salt thereof and arginine or a salt thereof are separately formulated so as to have the above-described molar ratio and mixed at the time of administration or taken simultaneously at the time of administration.

The above-mentioned pharmaceutical carrier means a pharmaceutically acceptable substance that exhibits as little pharmaceutical activity as possible in the body. Pharmaceutical carriers when administered orally include binders such as hydroxypropylcellulose, tragacanth gum, gum arabic, corn starch, gelatin; excipients such as dicalcium phosphate; partially pregelatinized starch, corn starch, potato starch, alginic acid, etc. Disintegrants; Lubricants such as magnesium stearate; Sweeteners such as sucrose; Dyes; Fragrances such as orange flavor; Solvents such as water, ethanol and glycerol; Nutrients such as proteins, amino acids, vitamins, lipids and glucose It can be used as appropriate.
In addition, pharmaceutically acceptable antioxidants such as cysteine, glutathione, ascorbic acid, sodium metasulfite, sodium bisulfite, and acid neutralizers such as calcium carbonate, aluminum hydroxide gel, and aluminum silicate are used as pharmaceutical carriers. Can be mentioned. One or more of these can be used.

The pharmaceutical dosage forms and pharmaceutical carriers described above are well known to those skilled in the art. For example, as described in Reimington's Pharmaceuticals Science, ed. 16 (1980), Mack Publishing Company. A dosage form can be used and a pharmaceutical carrier can be used.

The content (total amount) of glutamic acid and arginine, which are active ingredients in the above-mentioned pharmaceutical (pharmaceutical preparation), is usually 0.01 to 100% by weight, preferably 0.1 to 100% by weight, more preferably 1 to 100% by weight.

The preventive / ameliorating agent of the present invention may be used in combination with other drugs. Examples of such drugs include acid secretion inhibitors such as H2 receptor antagonists and proton pump inhibitors, 5-HT receptor agonists, D ₂ Motor function improvers such as antagonists, antacids such as muscarinic receptor antagonists, antigastrin drugs, and anticholinergics, teprenone, pranotol, ornoprostil, enprostil, misoprostol, rebamipide, sucralfate, polaprezinc, azulene In addition, mucosal protective agents such as egalene sodium, glutamine, aldioxa, gefarnate and ecabet sodium, sulfasalazine, 5-ASA preparations, inflammatory colitis therapeutic agents such as steroids and remicades can be contained. These can contain 1 type, or 2 or more types. Further, the preventive / ameliorating agent of the present invention and the other drug may be a single preparation or separate preparations, and may be administered simultaneously or with a time difference.

Next, the food according to the present invention contains glutamic acid or a salt thereof, and arginine or a salt thereof as active ingredients (excluding glutamic acid arginine salt), improves functional gastrointestinal disorders, functional gastroenteropathy or gastroesophageal reflux Taken for a specific purpose, such as prevention or amelioration of the disease. Moreover, the food of the present invention may be a general food including so-called health food. Furthermore, the food of the present invention can be a health functional food, a food for specified health use, a nutritional functional food, or a dietary supplement (dietary supplement) as defined in the health functional food system of the Ministry of Health, Labor and Welfare. In this case, glutamic acid and arginine, or a salt thereof can be used in combination of two or more. Further, the present invention also includes a form in which glutamic acid or a salt thereof and arginine or a salt thereof are separately formulated so as to have the above-described molar ratio and mixed at the time of ingestion or taken simultaneously at the time of ingestion.

The food of the present invention may be ingested the above-mentioned compound as it is, but in order to make it easier to ingest, the above-mentioned compound is added with normal food materials, seasonings, flavors, etc., drinks, gums, powders, tablets , Processed into a granule, jelly form, etc. In this case, for example, a tablet comprising the above compound and a disintegrant, a mixture of the above compound and a bulking agent (protein hydrolyzate, starch, casein, glucose, etc.), the above compound and a sticky agent that can be sustainedly released in the oral cavity ( A mixture of the above compound and a solvent (for example, edible oil, ethanol or water) in which the compound is dissolved, a W / O or O / W emulsion containing the compound, It can be set as the mixture of the said compound and nutrients (For example, protein, an amino acid, a vitamin, a lipid, glucose, etc.). In addition, glutamic acid and arginine for preventing or improving functional gastrointestinal tract disorders according to the present invention and for preventing or improving functional gastroenteropathy or gastroesophageal reflux disease can be added at the time of taking a meal and taken together with the meal. It is. For example, you may ingest by adding to existing foods, such as a drink, a soft drink, a yogurt, a jelly, and a milk drink.

When the food of the present invention is used for the specific purpose described above, the daily intake amount for adults is usually 0.01 to 10 g as glutamic acid, and preferably 0.1 to 3 g. Similarly, arginine is usually 0.01 to 10 g, preferably 0.1 to 3 g.

The daily intake amount of an active ingredient in which glutamic acid and arginine are combined is preferably 0.01 to 20 g, more preferably 0.01 to 10 g, still more preferably 0.1 to 6 g as glutamic acid and arginine.
Such intake can be administered once or divided into several times.
On the other hand, the content of the above compound in the food of the present invention is usually 0.01 to 3% by weight, preferably 0.05 to 1% by weight, more preferably 0.1 to 0.5% by weight. .

Moreover, the food of the present invention includes a form packaged in the form of one meal intake unit. The form of one meal intake unit is a form in which the amount taken per meal is determined in advance, and is determined in consideration of the above-mentioned intake of active ingredients per day for adults. For example, in the case of beverages, candy, chewing gum, jelly, pudding, yogurt, etc., there are forms that define a certain amount in packs, packaging, bottles, etc. In the case of granules, powders, slurry foods, packaging etc. A certain amount can be defined by the above, or the amount of intake per meal is displayed on a container or the like.

In another aspect, functional digestion comprising administering or ingesting an effective amount of glutamic acid or a salt thereof, and arginine or a salt thereof (excluding glutamic acid arginine salt) to a subject suffering from a functional gastrointestinal disorder Methods for preventing, ameliorating or treating vascular disorders are also included in the present invention. Effective amounts and the like are as described above.

As another aspect, the present invention also includes glutamic acid or a salt thereof and use of arginine or a salt thereof (excluding glutamic acid arginine salt) for producing a functional gastrointestinal disorder preventive / ameliorating agent. The functional gastrointestinal disorder preventive / ameliorating agent is as described above.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.

<Example 1>
In order to examine the promotion of gastric emptying when the mixing ratio of glutamic acid and arginine was changed, the following experiment was conducted.
Male SD (IGS) rats were used. 1.5 mL of 10% casein liquid diet containing 0.05% phenol red and test drug was orally administered, and 60 minutes later, the thoracotomy was performed and the stomach was removed. The excised stomach was placed in 0.1N sodium hydroxide (30 mL), homogenized and left at room temperature for 1 hour. 1 mL of acetonitrile was added to 0.5 mL of the supernatant and centrifuged (3000 rpm, 20 minutes). The absorbance of the supernatant was measured with an absorptiometer (560 nm). The gastric emptying rate was determined by the following calculation formula.

Gastric emptying rate (%) = (1−absorbance of test sample / absorbance of standard sample) × 100
The absorbance of the standard sample was that of the stomach extracted immediately after administration of 1.5 mL of 0.05% phenol red solution. The test drug was mixed in a phenol red solution. For glutamic acid, sodium glutamate was used, and for arginine, arginine hydrochloride was used. When the compounding ratio of glutamic acid and arginine was 1: 3, it was prepared and administered at 3 mM: 9 mM (Arg3Glu9) and 3: 1 respectively at 9 mM: 3 mM (Arg9Glu3). As a control, a 10% casein liquid diet containing 0.05% phenol red was used (vehicle).

The test was performed using one-way analysis of variance followed by Dunnett's multiple comparison. In addition, * P <0.05 is shown. The results are shown in FIG. The number of cases in each group is 16 (15 cases only in the vehicle group). The vertical axis represents the gastric emptying rate. It was shown that gastric emptying was promoted at any mixing ratio of glutamic acid and arginine. *

<Example 2>
In order to examine the promotion of gastric emptying when the mixing ratio of glutamic acid and arginine was changed, the following experiment was conducted.
Male SD (IGS) rats were used. 1.5 mL of 10% casein liquid diet containing 0.05% phenol red and test drug was orally administered, and 60 minutes later, the thoracotomy was performed and the stomach was removed. The excised stomach was placed in 0.1N sodium hydroxide (30 mL), homogenized and left at room temperature for 1 hour. 1 mL of acetonitrile was added to 0.5 mL of the supernatant and centrifuged (3000 rpm, 20 minutes). The absorbance of the supernatant was measured with an absorptiometer (560 nm). The gastric emptying rate was determined by the following calculation formula.

Gastric emptying rate (%) = (1−absorbance of test sample / absorbance of standard sample) × 100
The absorbance of the standard sample was that of the stomach extracted immediately after administration of 1.5 mL of 0.05% phenol red solution. The test drug was mixed in a phenol red solution. For glutamic acid, sodium glutamate was used, and for arginine, arginine hydrochloride was used. The concentration of glutamic acid was 9 mM, and the concentration of arginine was changed. As a control, a 10% casein liquid food containing 0.05% phenol red was used. The test was divided into two days of arginine-added 0.09, 0.03 and 0.3 mM and 0.9, 3, 30, 90, 300 and 900 mM, and a vehicle group was established each time (vehicle and vehicle 2). ).

The test was performed using one-way analysis of variance followed by Dunnett's multiple comparison. The combination group with 0.09 mM to 0.3 mM arginine was compared with vehicle, and the combination group with arginine 0.9 to 900 mM was compared with vehicle 2. In addition, * P <0.05 is shown. The results are shown in FIG. The number of examples in each group is 8. The vertical axis represents the gastric emptying rate (gastric emptying ability). Gastric emptying was significantly promoted when the addition concentration of arginine was 0.9 mM to 90 mM.

Formulation Example 1 (Granule)
Each component is pulverized and mixed in a pulverizer at a ratio of 0.56 g of sodium L-glutamate, 0.21 g of L-arginine hydrochloride and 1.0 g of partially pregelatinized starch as a single intake. Then, ethanol is added and kneaded with a kneader, and granulated with an extrusion granulator to obtain granules.

Formulation Example 2 (granule)
Each component was pulverized and mixed in a pulverizer at a ratio of 0.19 g of sodium L-glutamate, 0.63 g of L-arginine hydrochloride and 1.0 g of partially pregelatinized starch as a single intake. Then, ethanol is added and kneaded with a kneader, and granulated with an extrusion granulator to obtain granules.

Formulation Example 3 (tablet)
For each tablet, 0.56 g of sodium L-glutamate, 0.21 g of L-arginine hydrochloride and 0.2 g of hydroxypropylcellulose are added and granulated. After drying, the mixture is granulated, mixed and compressed to obtain tablets.

Formulation Example 4 (tablet)
For each tablet, 0.19 g of sodium L-glutamate, 0.63 g of L-arginine hydrochloride and 0.2 g of hydroxypropylcellulose are granulated. After drying, the mixture is granulated, mixed and compressed to obtain tablets.

Although several specific embodiments of the present invention have been described in detail, those skilled in the art will recognize that various modifications may be made to the specific embodiments shown without departing from the teachings and advantages of the invention. It is possible to make changes. Accordingly, all such modifications and changes are intended to be included within the spirit and scope of the present invention as claimed.

This application is based on Japanese Patent Application No. 2008-061769 filed in Japan, the contents of which are incorporated in this application.

Claims

Functional glutamic acid disorder preventive / ameliorating agent containing glutamic acid or a salt thereof and arginine or a salt thereof as an active ingredient except for glutamic acid arginine salt.
The preventive / ameliorating agent according to claim 1, wherein the functional gastrointestinal tract disorder is upper gastrointestinal tract disorder.
The preventive / ameliorating agent according to claim 2, wherein the upper gastrointestinal dysfunction is functional gastroenteropathy or gastroesophageal reflux disease.
The preventive / ameliorating agent according to any one of claims 1 to 3, wherein a molar ratio of glutamic acid or a salt thereof to arginine or a salt thereof is blended at 30: 1 to 1:30.
The preventive / improving agent according to claim 4, wherein the molar ratio is 10: 1 to 1:10.
The preventive / ameliorating agent according to claim 4, wherein the molar ratio is 10: 1 to 2: 1, and 1: 2 to 1:10.
The preventive / ameliorating agent according to claim 4, wherein the molar ratio is 10: 1 to 2: 1.
A medicament comprising the preventive / ameliorating agent according to any one of claims 1 to 7.
A food containing the preventive / ameliorating agent according to any one of claims 1 to 7.
The food according to claim 9, wherein the food is a health functional food, a food for specified health use, a nutritional functional food, or a dietary supplement.
∙ A method for preventing or ameliorating functional gastrointestinal disorders, including administering an effective amount of glutamic acid or a salt thereof, and arginine or a salt thereof to a subject suffering from functional gastrointestinal disorders, except for glutamic acid arginine salts.
∙ A method for treating functional gastrointestinal disorders, including administering an effective amount of glutamic acid or a salt thereof, and arginine or a salt thereof to a subject suffering from functional gastrointestinal disorders, except for glutamic acid arginine salts.
Use of glutamic acid or a salt thereof and arginine or a salt thereof for producing the preventive / ameliorating agent according to claims 1 to 7, except for an arginine salt of glutamic acid.